Program
tecotabart vedotin
Also written as “LM-302” and “LM-302 Injection”.
In Sino Biopharmaceutical’s pipeline, Claudin18.2 ADC
. Its studies are mostly in Adenocarcinoma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceuticalits history only | 53 open or running | phase 3since Mar 15, 2024 | Dec 5, 2021 | Oct 2028phase 3 · NCT07385703 |
| Bristol-Myers Squibb | 10 open or running | phase 1since Jul 27, 2021 | Jul 27, 2021 | none ahead |
- Named in Sino Biopharmaceutical’s own pipeline as
LM-302
, phase 3, as of Nov 16, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bristol-Myers Squibb only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jul 27, 2021First study: phase 1 study in Advanced Solid TumorFirst studyNCT05001516 · 17 enrolled · United States
- Feb 29, 2024Named tecotabart vedotinINNProposed as its International Nonproprietary Name in WHO's List 130 · before, LM-302
TargetBeta
“Claudin18.2 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) claudin 18.2 (CLDN18.2; A2 isoform of claudin-18) ”NCIt, by rule
Other programs on CLDN18
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zolbetuximabrule | Astellas Pharma | phase 4 | 12 |
| sonesitatug vedotin | AstraZeneca | phase 3 | 7 |
| garetatug rezetecan | Jiangsu HengRui Medicine | phase 3 | 7 |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905rule | Qilu Pharmaceutical | phase 3 | 6 |
| arcotatug tavatecanrule | Innovent Biologics | phase 3 | 5 |
| terallethrinrule | FutureGen Biopharmaceutical (Beijing) | phase 3 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1 | biokin-shanghai-biopharmaceutical-co-ltd | phase 3 | 3 |
| emaretamigrule | Astellas Pharma | phase 3 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200rule | Sichuan Kelun Pharmaceutical | phase 2 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate ASP546Crule | Astellas Pharma | phase 2 | 2 |
| givastomigrule | i-mab-biopharma-us-limited | phase 2 | 2 |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863 | AstraZeneca | phase 2 | 1 |
Studies
The one study Bristol-Myers Squibb leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05001516Advanced Solid Tumor · United States | 1 | Completed | Jan 4, 2024 | 17 |
How it is read
Names in the registry
- “LM-302”, 5 entries
- “LM-302 Injection”, 2 entries
Conditions, from the studies’ own filings
- Adenocarcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.